Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.

David Cella, Robert J. Motzer, Homa Dastani et al.|Journal of Clinical Oncology|2016

Cited by 4